Balyasny Asset Management
CRBP icon

Balyasny Asset Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Balyasny Asset Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$612K Sell
65,201
-68,110
-51% -$573K ﹤0.01% 2272
2025
Q4 		$1.09M Buy
133,311
+109,893
+469% +$1.36M ﹤0.01% 2154
2025
Q3 		$296K Buy
+23,418
New +$223K ﹤0.01% 2583
2024
Q4 		– Sell
-39,516
Closed -$815K – 2823
2024
Q3 		$815K Buy
+39,516
New +$2.02M ﹤0.01% 2045

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Balyasny Asset Management's CRBP Position: Q1 2026 in Review

Balyasny Asset Management reduced its Corbus Pharmaceuticals (CRBP) stake by 51% in Q1 2026, selling an estimated $573K and leaving 65,201 shares worth $612K. The position accounts for ﹤0.01% of the portfolio, ranked #2272.

Balyasny Asset Management first reported a position in CRBP in Q3 2024 and has held it in 4 quarters since. The position peaked at $1.09M in Q4 2025. 107 funds tracked by Wall St. Rank hold CRBP as of Q1 2026.

  • Balyasny Asset Management held 65,201 shares of Corbus Pharmaceuticals worth $612K as of Q1 2026.
  • Balyasny Asset Management sold 68,110 Corbus Pharmaceuticals shares in Q1 2026, an estimated $573K.
  • Corbus Pharmaceuticals made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #2272 holding.
  • Balyasny Asset Management first reported a position in Corbus Pharmaceuticals in Q3 2024 and has held it in 4 quarters since.
  • Balyasny Asset Management's Corbus Pharmaceuticals position peaked at $1.09M in Q4 2025.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.